H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics (VYNE) to Neutral from Buy.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- Why Is VYNE Therapeutics Stock (VYNE) Down 70% Today?
- VYNE Therapeutics Ends Phase 2b Trial for Repibresib
- VYNE says Phase 2B trial with repibresib gel did not meet primary endpoint
- Promising Developments in VYNE Therapeutics’ Repibresib Gel for Nonsegmental Vitiligo Drive Buy Rating
- Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study